N. Palacios

Integrative Approach to Predict Severity in Nonketotic Hyperglycinemia

D. Zafeiriou, G. Horvath, G. Hoffmann, 2022, Annals of neurology.

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.

G. L. Masson, W. Löscher, P. Vermersch, 2017, The Lancet. Neurology.

Insights into the expanding phenotypic spectrum of inherited disorders of biogenic amines

D. Zafeiriou, M. Verbeek, H. Goez, 2021, Nature Communications.

The association of COVID-19 occurrence and severity with the use of angiotensin converting enzyme inhibitors or angiotensin-II receptor blockers in patients with hypertension

D. Berlowitz, L. Kazis, W. Xia, 2021, PloS one.

Volumetric study of brain MRI in a cohort of patients with neurotransmitter disorders

C. Stephan-Otto, Jordi Muchart López, T. Opladen, 2022, Neuroradiology.

‘Minimal symptom expression’ in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab

P. van Damme, M. Benatar, F. Piehl, 2020, Journal of Neurology.